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SUMMARY
The cell of origin of pancreatic ductal adenocarci-
noma (PDAC) has been controversial. Here, we
show that identical oncogenic drivers trigger PDAC
originating from both ductal and acinar cells with
similar histology but with distinct pathophysiology
and marker expression dependent on cell of origin.
Whereas acinar-derived tumors exhibited low AGR2
expression and were preceded by pancreatic intrae-
pithelial neoplasias (PanINs), duct-derived tumors
displayed high AGR2 and developed independently
of a PanIN stage via non-mucinous lesions. Using
orthotopic transplantation and chimera experiments,
we demonstrate that PanIN-like lesions can be
induced by PDAC as bystanders in adjacent healthy
tissues, explaining the co-existence of mucinous
and non-mucinous lesions and highlighting the need
to distinguish between true precursor PanINs and
PanIN-like bystander lesions. Our results suggest
AGR2 as a tool to stratify PDAC according to cell of
origin, highlight that not all PanIN-like lesions are pre-
cursors of PDAC, and add an alternative progression
route to the current model of PDAC development.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) remains a growing
problem, despite efforts to improve diagnosis and therapy.
A better understanding of early PDAC events and cellular biology
are needed for improved clinical success (Ying et al., 2016).
Four types of pre-neoplastic PDAC precursors have been iden-
tified: intraductal papillarymucinousneoplasia (IPMN), pancreatic
mucinous cystic neoplasm (MCN), intraductal tubular papillary
neoplasm (ITPN), and pancreatic intraepithelial neoplasia (PanIN)
(Cooperetal., 2013;Hrubanetal., 2000a,2007). Theseprecursors
are associated with different PDAC prognoses (Cooper et al.,
2013; von Figura et al., 2014). However, PanIN lesions can co-
exist with other types of pre-neoplastic lesions (Brosens et al.,
2015; Verbeke, 2010). This raises important issues regarding the
independence and role of different lesions in progressing to
PDAC. Understanding the different origins and progression of
PDAC tumors will illuminate PDAC biology and could identify bet-
ter markers allowing patient stratification in the clinic.
Due to late-stage diagnosis of human PDAC, genetically engi-
neered mouse (GEM) models are the best tool to study PDAC
early development. Expression of oncogenic KRas in adult
mouse acinar cells, together with an inflammatory environment,
can induce transdifferentiation into duct-like cells (known as
acinar-to-ductal metaplasia [ADM]), formation of PanIN lesions,
and culmination in PDAC (Guerra et al., 2007; Habbe et al.,
2008; Kopp et al., 2012). However, human pancreatic tumor his-
tology has previously implicated the ductal compartment in
PDAC (Cubilla and Fitzgerald, 1976; Hruban et al., 2000b).
Whether pancreatic duct cells can give rise to PDAC has been
controversial. Adult mouse duct cells do not develop PDAC with
activation of mutant KRas only (Brembeck et al., 2003; Kopp
et al., 2012; Ray et al., 2011). With additional genetic alterations,
duct cells originate PDAC, but less efficiently compared to acinar
cells (Bailey et al., 2016), or forming less malignant tumors
(von Figura et al., 2014). Whether these differences are due to
the particular oncogene combination, or an intrinsic resistance
of duct cells to oncogenic transformation, is unclear.
To understand the early events of PDAC formation from
different cell types, we generated GEM models combining
endogenous oncogenic KRas activation (KRasG12D) (Hingorani
et al., 2003) with inactivation of either p53 (KP mice) or the
Fbw7 tumor suppressor (KF mice) induced in either adult acinar
cells (using Elastase1-CreERT2) or adult duct cells (using
Ck19-CreER). In both genotypes, both acinar and duct cells
gave rise to PDAC, but with distinct pathophysiology. While
acinar cells gave rise to PanINs that progressed to PDAC,
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Figure 1. Fbw7 Embryonic Deletion Drastically Accelerates KRasG12D-Induced Murine PDAC and Induces an Initial Ductal Transformation
(A) Schematic representation of the KFC (KRasLSL-G12D/wt; Fbw7F/F; Pdx1-Cre) mouse model. Cre expression is driven by the Pdx1 promoter. Black triangles
indicate loxP sites. Asterisk indicates G12D point mutation.
(B) Immunofluorescence staining of CK19 and pH3 in pancreas of Pdx1-Cre control and KFCmice at postnatal day 0 (P0). White arrowheads indicate pH3+ duct
cells; yellow arrowheads indicate pH3+ acinar cells.
(C) Quantification of pH3+ cells in acinar or ductal compartments of three P0 Pdx1-Cre and three KFC mice (as a percentage of total cells in that compartment).
Mice were obtained from two independent litters. Each data point represents one pancreatic region used for quantification. Graph shows mean values ± SD.
The p values were calculated using Welch’s t test (n = 3).
(legend continued on next page)
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duct-derived tumors did not develop via PanINs or other
mucinous precursors, and instead developed exclusively via
non-mucinous tubular lesions. Additional PanIN-like lesions
were induced by PDAC tumors as ‘‘bystanders’’ arising from
adjacent normal pancreatic tissue. Besides differences in
precursor lesions, we identified AGR2 as a biomarker that
discriminates acinar- and duct-derived tumors. These results
describe a second major route of PDAC progression.
RESULTS
Fbw7 Embryonic Deletion in a KRasG12D-Driven PDAC
Model Induces Duct Overproliferation and
Transformation
Fbw7alterationhasbeenassociatedwithPDACbiology (Calhoun
et al., 2003; Ji et al., 2015; Pe´rez-Mancera et al., 2012).Whilemu-
tations inFBW7are infrequent, Fbw7 is downregulatedat thepro-
tein level in PDACpatients (Ji et al., 2015). Additionally, Fbw7acts
as a tumor suppressor in a KRasG12D-driven PDAC embryonic
model (Zhang et al., 2016). Among all pancreatic compartments,
duct cells exhibit the highest levels of Fbw7 gene expression, and
Fbw7 deletion in pancreatic progenitors by Pdx1-Cre leads to an
expansion of the ductal compartment (Sancho et al., 2014), sug-
gesting that duct cells might participate in PDAC tumorigenesis
following Fbw7 loss. To test this, we induced homozygous dele-
tion of the Fbw7F/F allele in the KRasG12D Pdx1-Cre (KC) PDAC
model (Hingorani et al., 2003) to generate KFC mice (Figure 1A).
Aspreviously observed (Zhanget al., 2016), Fbw7deletiongreatly
accelerated PDAC onset and markedly decreased the median
survival of KFC mice compared with KC mice without changing
the tumor type (FiguresS1A–S1D). Thepercentageofmitoticcells
in the ducts of adult Fbw7F/F; Pdx1-Cre (FC) mice was signifi-
cantly increased compared with that in Pdx1-Cre age-matched
controls, but in the acinar compartment no change in proliferation
was observed (Figure S2A). In KFCmice, to avoid artifacts due to
secondary effects of tumorigenesis, only very early stages of
development (post-natal day 0 [P0]) were analyzed. As before,
no increase in proliferation was detected in acinar cells, whereas
the ductal compartment showed a marked increase in the
number of mitotic cells compared with controls (Figures 1B and
1C), indicating that Fbw7 deletion triggers overproliferation spe-
cifically in the ductal compartment.
To understand the course of PDAC development in KFC mice,
we performed a detailed time course of histological analysis
(Figure 1D), alongside pancreatic samples from Pdx1-Cre mice
to distinguish oncogene-related alterations fromnormal postnatal
changes in pancreatic morphogenesis (Shih et al., 2013) (Fig-
ure S2B). KRas oncogenic activation in the embryonic pancreas
does not disturb pancreatic development, and initial transforma-
tion events are only, and rarely, detected 2 weeks after birth (Hin-
gorani et al., 2003). In contrast, in KFC mice, Ck19-expressing
low- and high-grade pre-neoplastic lesions were already evident
7 days after birth, presenting multifocal ductal structures with
papillary architecture, pseudo-stratified epithelium, loss of cell
polarity, and fibroinflammatory reaction (Figure 1D, 3, 6, 9).
Although pancreata of newborn (P0) KFC mice (Figure 1D, 1)
had a composition and architecture similar to that of controls (Fig-
ure S2B, 1), the ducts were already hyperplastic, with frequent
mitotic figures (Figure 1D, 4). At P3, duct cells exhibited atypia,
with increased nuclear/cytoplasmic ratio (Figure 1D, 2, 5). Acinar
cells from KFC mice did not show any obvious Ck19 expression
at P0 and P3 (Figure 1D, 10, 11), suggesting absence of ADM
before the onset of ductal atypia. Ductal transformation in the
KFC model preceded the formation of dysplastic lesions, which
were detected for the first time at P7 (Figures S2C and S2D).
Both Duct and Acinar Cells in the Adult Give Rise to
PDAC but with Different Pathophysiology
Given the duct cell atypia observed in the KFC model, we gener-
ated a conditional model where Fbw7 deletion and simultaneous
KRasG12D activation could be induced specifically in adult
duct cells using Ck19-CreER (KFCk mice, Figure 2A). KFCk mice
induced at 8 weeks developed carcinoma approximately 2
months after oncogene activation. KFCk tumors exhibited
dysplasia of ductal epithelium with tufting, and positive staining
for HES1 and pERK (Figure 2B), as described for human and
murine PDAC (Bardeesy et al., 2006; Hingorani et al., 2003).
At the time of oncogene activation (day 0), no alteration was
detected in KFCk pancreas compared with wild-type controls,
except a possible crowding of the ducts (Figure 2C). At day 14,
although the acinar compartment remained morphologically
unchanged, ducts became noticeably hyperplastic and 15%
exhibited a duct cell expansion toward the lumen. At day 21,
over 20%of ducts showed cell expansion and approximately 4%
of the ducts showed dysplasia including tufting and shedding of
cell clusters into the lumen. Loss of duct cell polarity, increasing
nuclear atypia, stratification, and the presence of cribriform-like
structures indicated the onset of carcinoma in situ, 1 month after
induction (Figures 2C and 2D).
To strengthen our characterization of duct-derived tumors, we
used a second genetic model, combining oncogenic KRas with
inactivationofp53 (KPCkmice) (FigureS3A).KPCkpre-neoplastic
lesions followed a similar histological progression as observed in
KFCkmice, andmucinous PanIN lesions could not be detected at
early stages of tumorigenesis (Figure S3B), suggesting that the
ductal origin, rather than Fbw7 deletion, may be responsible for
the PanIN-independent mode of tumor progression.
To assess PDAC formation in acinar cells, we used Elastase
1-CreER to induce Fbw7 deletion and KRasG12D activation (KFE
model, Figure 3A). Cerulein treatment was used to induce
chronic pancreatitis and promote PDAC formation from adult
acinar cells (Carrie`re et al., 2011; Guerra et al., 2007) (Figure 3A).
Six months after tamoxifen treatment, KFE animals developed
PDAC characterized by the widespread growth of dysplastic
(D) Time-course analysis of tumor development in KFCmice. (1–3) H&E low-magnification images. Black boxes indicate area magnified in images 4–6. White box
highlights presence of mitotic figures in KFC ductal cells at P0. White arrows show mitotic figures. Black arrow shows loss of polarity (nuclear orientation). Black
dotted lines highlight duct cell dysplasia. White dotted lines highlight pseudostratified epithelium. (7–11) CK19 IHC analysis of ductal cells (7–9) and acinar cells
(10–11). For each time point, two litters, each comprising at least two KFC animals, were analyzed. Scale bars in panels 1–3 represent 100 mm. Scale bars in
panels 4–11 represent 50 mm. See also Figures S1 and S2.
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Figure 2. Carcinoma Initiated in Duct Cells Progresses Independently of Low-Grade PanIN Formation
(A) Schematic representation of the KFCk (KRasLSL-G12D/wt; Fbw7F/F; Ck19-CreER) mouse and time-course experimental approach. Black triangles indicate
loxP sites; asterisk indicates the G12D mutation.
(B) Histological analysis of KFCk-derived carcinoma 2 months after tamoxifen treatment. Boxes indicate enlarged regions.
(legend continued on next page)
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Ck19-expressing ductal structures (Figure 3B). In contrast with
duct-derived PDAC, lesions resembling low-grade PanINs
were readily identified in KFE pancreas 1 month post-tamoxifen
induction, well before the appearance of PDAC (Figure 3C). In
late-stage carcinoma, although PanIN-like lesions were found
in both acinar- and duct-derived tumors, acinar-derived carci-
noma was associated with significantly more of these lesions
(Figure 3D). Thus, even in the context of the same genetic alter-
ation, acinar- and duct-derived tumors show clear differences in
pathophysiology.
To better understand the nature and origin of PanIN-like
lesions observed in these mouse models, we combined the
acinar-targeted KFE and duct-targeted KFCk models with a
Rosa26-LSL-YFP lineage tracer to distinguish recombined cells
harboring oncogenic gene alterations from unrecombined wild-
type cells (Figure 3E). Following tamoxifen treatment, plus
cerulein for acinar-targeted models, both KFCkY and KFEY
mice developed YFP-traced tumors. Interestingly, although in
the KFEY model most of the PanIN-like lesions were both YFP
and AB/PAS positive, with a minority not lineage-traced, in the
duct-derived model (KFCkY) none of the PanIN-like lesions
were lineage traced (Figure 3F). We inferred that the acinar-
derived KFEY model develops predominantly ‘‘true’’ PanINs,
which precede tumor onset and harbor the same oncogenic
alterations as the tumor, whereas in the KFCkY model, PanIN-
like lesions are less common, appear later, and are composed
of cells that did not undergo Cre-mediated recombination of
KRasG12D and Fbw7F/F alleles.
PDAC Tumors Induce PanIN-like Lesions in Adjacent
Wild-Type Tissue
The absence of lineage tracing observed in the PanIN-like
lesions in the KFCkY model suggested that these lesions may
be derived from wild-type tissue adjacent to the tumor. To test
this hypothesis, we performed orthotopic injections of lineage-
traced PDAC cells from KRasLSL-G12D/WT; P53F/F; Pdx-Cre;
Rosa26-LSL-YFP (KPCY) mice. To exclude rare non-traced
tumor cells, we sorted KPCY tumor cells for the YFP tracer
before orthotopic transplantation (Figure 4A). Transplantation
of KPCY cells led to efficient YFP-labeled PDAC formation in
the host pancreas (Figure 4B). As in the KFCkY model, YFP-
negative low-grade PanIN-like lesions positive for AB/PAS and
Muc5AC were observed in close proximity to the tumor (Fig-
ure 4B). Thus, some low-grade PanIN-like lesions appear to be
induced in host tissue as ‘‘bystanders’’ of PDAC growth.
To confirm thewild-type origin of the PanIN-like lesions, and to
exclude the possibility that in vitro culture of primary PDAC tumor
cells or orthotopic transplantation surgery could contribute to
their induction, we performed PDAC/wild-type chimera experi-
ments. Embryonic stem cells were generated from KPCY
animals, and injected into host blastocysts ubiquitously express-
ing tdTomato (recognized by the RFP antibody). In the resulting
chimeric mice, PDAC derived from the KPCY embryonic stem
cells (ESCs) is YFP-labeled, whereas wild-type blastocyst-
derived tissue is marked by tdTomato/RFP (Figure 4C). Histolog-
ical analysis revealed YFP-positive PDAC, interspersed with
RFP-positive stromal cells (Figure 4D). Importantly, we detected
AB/PAS-positive low-grade PanIN-like lesions that were YFP-
negative and RFP-positive, demonstrating their wild-type
‘‘bystander’’ origin (Figure 4D). These experiments confirm that
PDAC tumors can induce PanIN-like lesions in the surrounding
wild-type tissue.
Tumors of Acinar and Ductal Origin Show Differences in
AGR2 Expression
The difficulty in distinguishing ‘‘true’’ PanINs from PanIN-like
lesions has implications for tumor classification and prognosis,
as the type of precursor lesion associated with the PDAC informs
clinical decision-making (Cooper et al., 2013; Distler et al., 2014).
Because some of the PanIN-like lesions identified at the time of
tumor detection are reactive changes, not precursors, additional
criteria are needed to aid PDAC stratification. To screen for po-
tential markers indicative of tumor origin, we triggered oncogenic
Ras activation and p53 inactivation in duct- and acinar-derived
cells in parallel using KPCkY (KRasLSL-G12D/WT; P53F/F; Ck19-
CreER; Rosa26-LSL-YFP) and KPEY (KRasLSL-G12D/WT; P53F/F;
Ela1-CreERT2; Rosa26-LSL-YFP) mouse strains (Figure 5A).
KPEY mice were also treated with cerulein to induce ADM.
After 20 days, three-dimensional (3D) tumor organoids were
established from YFP-positive cells from both models, and
analyzed for the expression of a panel of genes described to
stratify PDAC tumors into clinically distinct categories (Collisson
et al., 2011) (Figure 5A). AGR2 (anterior gradient protein 2)
showed the highest difference in mRNA level, being upregulated
approximately 800-fold in duct-derived compared with acinar-
derived tumor organoids (Figure 5B).
To determine whether AGR2 marks duct-derived PDAC, we
transplanted duct- and acinar-derived KP organoids into the
pancreas of NuNu mice to generate orthotopic allograft tumors
(duct-OA and acinar-OA, respectively). Organoids from both
origins generated YFP-traced invasive PDAC tumors embedded
in dense YFP-negative fibrous stroma (Figure 5C), which were
morphologically indistinguishable and consistent with the histol-
ogy of KP pancreatic tumors (Bardeesy et al., 2006). However,
duct-OA tumors showed widespread AGR2 staining, whereas
acinar-OA tumors were low or negative for AGR2 (Figures 5C,
5D, S4A, and S4B). The differences in AGR2 expression were
also observed by Q-PCR (Figure S4C).
(C) IHC analysis of wild-type (WT) 8-week-old pancreas and time-course analysis of carcinoma development in the KFCk model. Regions of interest marked in
low-magnification H&E images are analyzed for AB/PAS staining and Ck19 immunological staining below. Black dashed line highlights ductal dysplasia. Black
arrowheads indicate loss of cell polarity. At least seven animals per time point were used, and four tissue sections per animal were obtained for H&E and
immunostaining.
(D) Quantification of the histological progression of duct-derived tumors from the KFCk model. At least three mice per time point and three tissue sections per
mouse were used. Ducts exhibiting dysplasia, tufting, or loss of polarity were counted in one category only. Bars indicate mean + SD. The percentage of ducts
with stromal expansion (stromal layer thicker than 50 mm) was quantified separately (line graph showsmean ± SD). Data points indicate individual tissue sections.
All scale bars represent 100 mm. See also Figure S3.
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Figure 3. PanIN and PanIN-like Lesions Are Fundamentally Different and Occur at Different Stages of Tumor Development
(A) Schematic representation of KFE (KRasLSL-G12D/wt; Fbw7F/F; Ela1-CreERT2) mice and experimental approach. Black triangles indicate loxP sites; asterisk
indicates G12D mutation.
(B) Histological analysis of acinar-derived tumors and corresponding CK19 IHC stain 6 months after cerulein treatment.
(legend continued on next page)
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To validate AGR2 as a marker of duct-derived PDAC, we
analyzed AGR2 immunohistochemistry (IHC) staining in pan-
creata from KFCk and KFE mice (Figures 5E, S4A, and S4B).
The extent of AGR2 staining and mRNA expression was signifi-
cantly higher in duct-derived (KFCk) compared with acinar-
derived (KFE) pancreatic lesions (Figures 5E and S4A–S4C).
Levels of AGR2 in PDAC inversely correlate with the extent of
epithelial-to-mesenchymal transformation (EMT) of the tumor
(Mizuuchi et al., 2015). In agreement with this finding, we
observed that mesenchymal tumor regions did not express
AGR2. To exclude EMT as a confounding factor in determining
tumor origin, we restricted our analysis to the tubular, epithelial
ductal cells. KPCY tumor cells that undergo EMT lose Ck19
expression (Figure S4D). Therefore, we assessed AGR2 expres-
sion in Ck19-expressing epithelial cells only. The difference be-
tween AGR2 levels in duct-derived and acinar-derived tumors
was maintained (Figures S4E and S4F), suggesting that AGR2
truly distinguishes PDAC tumors of different origins.
Interestingly, KFCk mice showed significantly reduced sur-
vival compared with KFE mice (Figure S5A). Reduced survival
was also observed in mice harboring duct-derived allografts
compared with acinar-derived allografts (Figure S5B), support-
ing differential prognosis of PDAC of different origins.
Some of the most commonly used mouse models of PDAC,
such as KPC (KRasLSL-G12D/WT; P53F/F; Pdx1-Cre), initiate onco-
gene expression at an embryonic stage, and the tumor cell of
origin is unclear (Guerra and Barbacid, 2013). Interestingly,
KPC PDAC tumors were heterogeneous for AGR2 staining,
with large focal areas either strongly positive or negative for
AGR2 (Figure 5F). Tumors of the same genotype derived from
adult duct or acinar cells displayed either high or low AGR2
staining, in duct-derived or acinar-derived PDAC, respectively
(Figure S4A). These observations are consistent with multifocal
PDAC derived from both acinar and ductal cells in the KPC
model (Maddipati and Stanger, 2015).
Differences in AGR2 Expression in Human PDAC
Although proof of cellular origin in human PDAC is not yet
possible, markers that stratify tumors according to origin in
mice could help to refine the classification of PDAC in patients.
Data from the human protein atlas (Uhle´n et al., 2015) suggest
that PDAC from different patients presents strongly divergent
patterns and levels of AGR2 protein (Figure S6). To confirm this
observation and control for differences in staining protocol, we
performed AGR2 IHC stainings on two independent commercial
tissue microarrays of human PDAC (US Biomax). We focused
only on cuboidal epithelial cells in our analysis to exclude the
effects of EMT on AGR2 levels (Mizuuchi et al., 2015). AGR2
staining patterns over 71 samples were highly divergent, with
morphologically similar tumors expressing very high or very
low levels of AGR2 (Figures 6A and 6B) as in our mouse models.
These data are consistent with the existence of two classes
of human PDAC tumors, which may be derived from acinar
and duct cells. Together with the analysis of pre-neoplastic
lesions, we speculate that analysis of AGR2 staining, specifically
in epithelial cells of the tumor, could be of value in stratifying
human PDAC.
DISCUSSION
Although studies of human PDAC originally put forward duct
cells as cells of origin of the disease (Cubilla and Fitzgerald,
1976; Hruban et al., 2000b), work in GEM PDAC models pro-
posed the acinar compartment as the principal contributor to
PDAC development (Kopp et al., 2012). Here, we show that
duct cells can initiate PDAC, giving rise to aggressive localized
carcinoma in response to two oncogenic combinations:
KRasG12D together with inactivation of Fbw7 (KF model), or
p53 (KP model). It is possible that duct cells are refractory to
the genetic alterations studied previously. Conversely, Brg1
deletion has been found to promote neoplasia specifically in
duct cells (von Figura et al., 2014). Alternatively, subtle differ-
ences in the CreER-driver lines employed (Ck19-CreER
compared to HNF1b-CreER and Sox9-CreER used previously)
may explain the altered duct cell susceptibility to transformation
compared with previous studies.
Although it is well established that acinar cells develop PDAC
in a PanIN-dependent manner (Guerra et al., 2007; Habbe et al.,
2008) (Figure 6C), we demonstrate here that duct cells respond
to the same oncogene activation by increasing proliferation,
expansion toward the duct lumen, and progression to PDAC, in-
dependent of PanIN pre-neoplastic lesions (Figure 6C). Interest-
ingly, the pre-neoplastic lesion associated with duct-derived
Ptf1a-Cre; KRasG12D; Brg1f/f tumors was IPMN (von Figura
et al., 2014), whereas duct-derived precursor lesions in our
models were exclusively non-mucinous. This suggests that,
although the cell of origin is the principal factor determining the
PanIN-dependent or independent course of tumor progression,
it is likely that the genotype is a modulating factor in determining
the course of duct-PDAC progression.
Despite the PanIN-independent progression, duct-derived
PDAC, like the majority of human pancreatic tumors, exhibited
(C) Histological analysis of KFE pancreas 1 month after cerulein treatment and corresponding CK19 and AB/PAS stain. Black box indicates region enlarged on
the right.
(D) AB/PAS representative images of acinar-derived (KFE) and duct-derived (KFCk) tumors, 6 and 2 months after tamoxifen treatment, respectively, and
respective quantifications of AB/PAS-positive PanIN-like lesions per 10mm2 of pancreatic area. Black arrows showAB/PAS-positive lesions. Black box indicates
region enlarged on the right. At least three mice per genotype and three tissue sections per mouse were used. Bar chart shows mean + SD. Data points indicate
scores for individual mice (n = 3 KFE mice; n = 11 KFCK mice). The p values were calculated using Welch’s t test.
(E) Schematic representation of the KFEY (KRasLSL-G12D/wt; Fbw7F/F; Ela1-CreERT2; Rosa26-LSL-YFP) and KFCkY (KRasLSL-G12D/wt; Fbw7F/F; Ck19-CreER;
Rosa26-LSL-YFP) mice and experimental approach. KFEY mice were treated as in Figure 3A and KFCkY mice as in Figure 2A.
(F) Co-stain of YFP and AB/PAS on tumor sections from KFEY and KFCkY pancreas, 6 and 2 months after tamoxifen treatment, respectively. Quantification
shows YFP-positive and -negative AB/PAS-positive PanIN-like lesions per 10 mm2 of pancreatic area. At least three mice per genotype and two tissue sections
per mouse were used. Bar chart shows mean + SD. Data points indicate scores for individual mice (n = 3 KFEY mice; n = 10 KFCk mice). The p values were
calculated using Welch’s t test. Scale bars represent 50 mm in (F) and 100 mm for the remaining panels.
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PanIN-like lesions at the time of diagnosis. Our lineage-tracing
studies, orthotopic allograft, and chimera results indicate that
mucinous PanIN-like lesions can be divided into true precur-
sor PanINs, which carry key oncogenic alterations, found
from the earliest stages and exclusively in acinar-derived
Figure 4. PDAC Oncogenesis Promotes
Low-Grade PanIN-like Lesion Formation in
Adjacent Wild-Type Tissues
(A) Schematic representation of the allograft
experimental approach. PDAC organoids from
5-week-old KPCY (KRasLSL-G12D/wt; p53F/F; Pdx1-
Cre; Rosa26-LSL-YFP) mice were sorted for YFP
before transplantation.
(B) Histological analysis of orthotopic allograft
tumors 20 days post-transplantation on serial
sections. Two independent procedures were
performed with four mice each. Black dashed line
delineates YFP-PDAC.
(C) Schematic representation of the chimera
experimental approach. KPCY (KRasLSL-G12D/wt;
p53F/F; Pdx1-Cre; Rosa26-LSL-YFP) embryonic
stem cells were injected into C57BL/6J Gt(ROSA)
26Sortm9(CAG-tdTomato)Hze mouse blastocysts to
generate chimeras with a low contribution of
YFP-expressing KPC cells in tdTomato+ healthy
tissues.
(D) Histological analysis of 4-month-old chimeric
pancreas on serial sections. Black dashed line
delineates the invasive front of the tumor. Black
boxes in (B) and (D) indicate high-mag regions. All
scale bars represent 100 mm.
tumors (Figure 6C), and PanIN-like
bystander lesions originating alongside
fully developed tumors regardless of
the cell of origin (Figure 6D). It is
consensus in the clinic that high-grade
PanIN lesions progress to PDAC, and
thus their presence should be instruc-
tive of follow-up or surgery. However,
the relevance of lower-grade lesions is
less clear (Patra et al., 2017). Definitive
diagnosis of pancreatic lesions in the
context of malignant disease is chal-
lenging, and there is difficulty in distin-
guishing ‘‘reactive changes’’ of the
epithelium from early PanINs (Hruban
et al., 2001; Strobel et al., 2007), lead-
ing to possible inclusion of the latter in
the PanIN classification and conse-
quent misinterpretation of the type of
PDAC. Although it has always been
accepted that the proportion of early
PanINs that progress to PDAC is low,
our findings highlight the possibility
that some lesions described as low-
grade PanINs are in fact PanIN-like
bystander lesions induced by the
adjacent tumor.
These findings validate several long-standing clinical observa-
tions. Low-grade PanIN-like lesions are also found in the context
of other pancreatic neoplasias such as pancreatic endocrine
tumors, serous cystadenomas, solid pseudopapillary tumors,
and ampullary tumors, which do not necessarily arise from
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Figure 5. AGR2 Level and Extent of Expression Indicates Tumor Cell of Origin
(A) Experimental approach to identify and validate potential cell of origin markers. Micrographs depict organoids used for gene expression analysis, derived from
YFP-sorted cells from KPCkY and KPEY mice 20 days after in vivo recombination using tamoxifen (Tam).
(B) Relative expression of selected genes used for PDAC classification in duct- and acinar-derived organoids, analyzed by qRT-PCR. Bar chart showsmean +SD.
(C) Histological analysis of orthotopic allograft (OA) tumors generated from duct- (KPCkY) and acinar-derived (KPEY) organoids.
(D) AGR2 blinded histological score (HScore) for four duct-OA tumors and three acinar-OA tumors, two sections per tumor. Dot plot shows mean ± SD.
(legend continued on next page)
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PanINs and do not progress to PDAC (Recavarren et al., 2011;
Stelow et al., 2006). Multicolor lineage tracing has demonstrated
that malignant PanIN lesions are clonal entities (Maddipati and
Stanger, 2015), expected to consist entirely of KRas mutant
cells. However, a meta-analysis of low-grade PanIN lesions in
human PDAC samples found that more than one-half do not
(E) AGR2 IHC stain of pancreatic pre-neoplastic lesions of three KFCk and three KFE animals, two sections per tumor, and respective HScore. Black boxes
indicate high-mag regions. Dot plot shows mean ± SD.
(F) H&E and IHC stain for AGR2 on PDAC from KPCY animals (KRasLSL-G12D/wt; p53F/F; Pdx1-Cre; Rosa26-LSL-YFP). Magnifications of AGR2 negative (i) and
positive (ii) regions are shown. Scale bars represent 100 mm except for micrographs in (A) and in (F) (left panels), which are 500 mm and 2 mm, respectively. The p
values were calculated using Welch’s t test. See also Figures S4 and S5.
Figure 6. Human PDAC Tumors Show
Distinct AGR2 Expression and Model
Comparing Duct- and Acinar-Derived
Tumors
(A) Representative histological (H&E) and IHC
analysis of AGR2 in human tumors on PDAC tissue
microarray (Pa1002a, US Biomax), showing one
AGR2 high core and one AGR2 low core. Black
boxes indicate magnified regions shown below.
(B) Quantification of AGR2 high/medium and low/
negative PDAC tumor cores from two independent
TMAs (Pa1001a and P1002a).
(C) Schematic summary of duct-derived versus
acinar-derived pancreatic tumor progression.
Acinar cells respond to oncogenic hits by under-
going acinar-to-ductal metaplasia (ADM) that
progresses to PanIN lesions (1–3) and culminates
in PDAC. In contrast, duct cells harboring onco-
genic mutations do not evolve into PanIN lesions
but increase proliferation, leading to a crowding of
the duct network and deformation of the ductal
structures. Ductal transformation progresses to a
stage resembling a non-mucinous carcinoma
in situ that culminates in PDAC formation. Mature
tumors from different origins are morphologically
similar but can be distinguished by their levels and
pattern of AGR2 expression and by the frequency
of PanIN-like lesions. Duct cell-derived tumors are
almost entirely AGR2-positive and present a
reduced number of PanIN-like lesions, whereas
acinar cell-derived PDAC only present focal
AGR2-positive regions and show abundant low-
grade PanINs.
(D) Schematic representation of the origin of non-
precursor PanIN-like lesions. The presence of
developed PDAC induces the formation of PanIN-
like bystander lesions originating from wild-type
tissue. These are the only low-grade PanIN-like
lesions found in duct-derived PDAC, but they are
also present in PDAC from other cell origins. See
also Figure S6.
harbor KRas mutations (Lo¨hr et al.,
2005). Using more sensitive sequencing
techniques, a later study detected KRas
mutations in most PanIN lesions, but
often with mutation frequencies below
10% (Kanda et al., 2012), not compatible
with a clonal origin. We speculate that
these ‘‘PanINs’’ are in fact PanIN-like bystander lesions, arising
in KRas wild-type tissue and possibly acquiring the mutation in
one or two cells after lesion formation. Thus, data from human
PDAC are consistent with the existence of PanIN-like bystander
lesions as well as fully KRas mutant PDAC precursor PanINs.
Because the only PanIN-like lesions occurring in murine
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duct-derived tumors are bystanders, thesemodels will be invalu-
able in future research into these changes induced by the tumor
in the surrounding tissue.
We have observed that PDAC originating in duct cells is asso-
ciated with lower survival, both in the KP allografts and in the
GEM models. Although additional studies have to be performed
to assess the metastatic potential that is so common among
pancreatic cancer patients, these data indicate that discrimi-
nating the origin of PDAC might inform patient prognosis.
Because the classification of PDAC based on the type of pre-
neoplastic lesion present at diagnosis is hampered by the pres-
ence of PanIN-like lesions, additional parameters will likely be
required. We identified anterior gradient 2 (AGR2) as a putative
marker of PDAC of ductal origin, and the marked differences in
AGR2 expression pattern in PDAC patient samples, in conjunc-
tion with quantification of pre-neoplastic lesions, may aid the
stratification of human PDAC tumors.
EXPERIMENTAL PROCEDURES
Mouse Lines
Ck19-CreER (Means et al., 2008), Ela1-CreERT2 (Desai et al., 2007), Fbw7F/F
(Jandke et al., 2011), KRasLSL-G12D/wt (Jackson et al., 2001), Nu/Nu (Flana-
gan, 1966), p53F/F (Marino et al., 2000), Pdx1-Cre (Hingorani et al., 2003),
Rosa26-LSL-YFP (Srinivas et al., 2001), and C57BL/6J Gt(ROSA)
26Sortm9(CAG-tdTomato)Hze (Madisen et al., 2010) mouse lines have been
previously described. These lines were intercrossed to obtain the different
genotypes in the study. All experiments performed in animals were
approved by the Crick (formerly London Research Institute) Animal
Ethics Committee and conformed to UK Home Office regulations under
the Animals (Scientific Procedures) Act 1986 including Amendment
Regulations 2012.
Tamoxifen and Cerulein Injection
Cre expression was induced in adult (8-week-old) Ck19-CreER and Ela1-
CreERT2 mice by intraperitoneal injections of tamoxifen (Sigma) dissolved in
peanut oil (Sigma) at a dose of 100mg/kg of body weight. For KFCk, tamoxifen
was injected once a day for 2 days, and for KFE, once a day for 5 days.
One week after tamoxifen treatment, KFE mice were intraperitoneally
injected with cerulein (Sigma) dissolved in PBS, at a dose of 40 mg/kg body
weight, three times a day on 3 days a week for 4 weeks, to induce chronic
pancreatitis.
Histopathology, IHC, and Immunofluorescence
Specimens were fixed overnight in 10% neutral buffered formalin, transferred
to 70% ethanol 16 h later, and embedded in paraffin. For histopathology,
paraffin-embedded pancreata were serially sectioned (3 mm) and every 20th
section was stained with H&E.
For IHC, 4-mmsectionswere deparaffinized inHisto-Clear (National Diagnos-
tics), followed by serial ethanol washes and water. Slides were subjected to
heat-mediated antigen retrieval by incubation in 10 mM sodium citrate
(pH 6.2) at 95C for 15 min. Endogenous peroxidase was inactivated (except
for IHC-immunofluorescence [IF]) with 1.6% H2O2 for 10 min, followed by
epitope blocking for 1 hr at room temperature with 1% bovine serum albumin
(Sigma-Aldrich), 5% normal donkey serum (EMD-Millipore), and 0.4% Triton
X-100 (Sigma-Aldrich) diluted in PBS. All primary antibodies were incubated
overnight at 4C, followed by secondary incubation with biotin-conjugated
antibodies for 45 min at room temperature or fluorescently conjugated anti-
bodies for 2 hr. IHC signal was obtained with the avidin-biotin complex (ABC)
solution (Vectastain ABC kit) and developed with peroxidase substrate
kit 3,30-diaminobenzidine (DAB) from Vector. IHC slides were counterstained
with Mayer’s hematoxylin, and IHC-IF slides were incubated with DAPI.
Antibodies used included the following: Ck19 (DSHB; Troma-III), GFP
(used for YFP) (Abcam; ab6673), Muc5ac (Thermo Fisher; MS-145-B), HES1
(Chemicon/Millipore; AB5702), pH3 (Santa Cruz; sc-8656-R), pErk (p44/42;
Cell Signaling; 4376), AGR2 (Atlas Antibodies; HPA007912), and RFP (Rock-
land/TEBU; 600-401-379).
Alcian Blue/Periodic Acid-Schiff and Co-stain with GFP
To detect mucinous structures, alcian blue/periodic acid-Schiff (AB/PAS)
staining was performed. Sections were deparaffinized by xylene treatment
twice for 5 min. Sections were incubated twice in 100% industrial methylated
spirits (IMS) and once in 70% IMS for 3 min each, followed by incubation with
AB 1% (in 3% acetic acid) for 5 min. Slides were washed intensively in tap
water and distilled water then incubated in 1% (w/v) periodic acid in distilled
water for 5min, washed again in distilled water, and incubated in Schiff (Fisher)
for 15 min, and then a 10-min wash in running tap water. Nuclei were counter-
stained with Mayer’s hematoxylin for 1 min. The stain was differentiated in 1%
acid alcohol for a few seconds (experimental slides performed in parallel) and
washed in tap water for 5min. Tissue was dehydrated in ethanol and cleared in
xylene, and slides weremountedwith coverslips using DPXmountingmedium.
For the combination of AB/PASwith GFP staining, GFP immunostaining was
performed first, followed by the AB/PAS staining procedure.
KPCY Tumor Cell Isolation and Organoid Cultures
PDAC from KPCY (KRasLSL-G12D/WT; P53F/F; Pdx-Cre; Rosa26-LSL-YFP)
animals was dissected, and cell dissociation was performed as described
(Reichert et al., 2013) with a few modifications. The dissected tumor was
immediately placed in 5 mL of cold G solution and kept on ice. Following
mechanical dissociation, the tissue was transferred to a 50-mL Falcon
with 15 mL of collagenase V (1 mg/mL in DMEM plus 1% [v/v] penicillin/strep-
tomycin [10,000 U/mL with no FCS]) and incubated for 20 min in a water bath
at 37C. To inactivate the digestion, 15 mL of ice-cold G solution were added.
The cell-dissociated PDAC was centrifuged at 300 3 g for 5 min with low
deceleration, the supernatant was discarded, and the pellet incubated in
trypsin-EDTA for 5 min at room temperature. To stop the reaction, 2 mL of
soybean trypsin inhibitor were added, followed by 15mL of ice-cold G solution
and centrifugation for 5 min at 300 3 g. The pellet was resuspended in 10 mL
of PBS with 2% (v/v) FCS and passed through a 70-mm filter. Cells were plated
in growth factor-reduced Matrigel to grow as 3D organoid cultures as
described (Huch et al., 2013).
Generation of Duct- and Acinar-Derived Organoids
KPCkY (KRasLSL-G12D/WT; P53F/F; Ck19-CreER; Rosa26-LSL-YFP) and KPEY
(KRasLSL-G12D/WT; P53F/F; Ela1-CreERT2; Rosa26-LSL-YFP) 8-week old animals
were intraperitoneally injected with tamoxifen, as above. KPEYmice were then
subjected to 1 week of cerulein-induced chronic pancreatitis to induce in vivo
ADM. Animals were sacrificed 20 days post-tamoxifen, and tumor cells were
isolated as described above. YFP-positive single cells (duct-derived KPCkY
and acinar-derived KPEY) sorted by fluorescence-activated cell sorting
(FACS) were grown as 3D organoids in growth factor-reduced Matrigel.
Orthotopic Transplantation
Duct- and acinar-derived organoids were dissociated into single cells by
trypsin treatment, and YFP-positive cells were isolated by FACS. The perito-
neum of anaesthetized Nu/Nu mice was surgically opened, and 150 3 103
tumor cells suspended in growth factor-reducedMatrigel (50 mL) were injected
in the pancreatic tail. The peritoneal wall was sutured with absorbable sutures,
and the skin was closed with clips. A 0.05 mg/kg dose of Vetergesic
was subcutaneously injected immediately after surgery. Tumors were
collected 20 days post-transplantation for the detection of PanIN-like
bystander lesions. For acinar and duct-derived allografts (acinar-OA and
Duct-OA), Nu/Nu mice were allowed to develop tumors up to 1 mm3.
KPCY ESCs and Generation of Chimeras
ESCs were generated as described (Czechanski et al., 2014) with minor
modifications. ESCs were obtained from KPCY mouse blastocysts and
derived in serum free (Gibco knockout serum replacement and DMEM)
conditions in the presence of LIF and PD 0325901 (MEK inhibitor). Following
two to three passages, ESCs were placed in standard serum medium (15%
plus LIF) and maintained in standard murine ESC (mESC) conditions.
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Chimera production was performed following previously published guidelines
(Behringer et al., 2003). KPCY ESCs were injected into C57BL/6J Gt(ROSA)
26Sortm9(CAG-tdTomato)Hze mouse blastocysts. Tumors of the KPCY/Tomato
chimeric mice were detected at 4 months of age.
AGR2 HScore
AGR2 scoring was performed by six independent observers as a blinded anal-
ysis. IHC staining intensities were scored for the duct-like structures in each
tumor from 0 (no staining) to 4 (high and widespread staining). Mean average
score for each tumor of each genotype was calculated. At least three mice per
genotype and two tissue sections per mouse were used.
AGR2 on Tissue Microarrays
Two independent tissue microarrays (TMAs) were acquired from US Biomax
(PA1001a and PA1002a). IHC for AGR2 was performed as above. Cores
were excluded if absent in the slide or if repeated between the TMAs. Two
additional cores were excluded due to differences in classification (high
AGR2 expression in one TMA and medium expression in the other). A total
of 71 cores were used for analysis.
Quantitative RT-PCR
RNA was isolated from dissociated organoids or paraffin-embedded tumors
using the RNeasy mini-kit (QIAGEN) or the RecoverAll Total Nucleic Acid Isola-
tion Kit (Ambion, Life Technologies), respectively. cDNA was generated using
the Transcriptor First Strand cDNA synthesis kit (Roche Diagnostics) and was
used for qPCR SYBR-Green (Life Technologies) detection using the primers
listed in Supplemental Experimental Procedures.
Statistics
Data were analyzed using GraphPad Prism software (GraphPad Software) and
presented as mean ± SD. Statistical analysis was performed using two-sided
Welch’s t test (with correction for unequal variance) for bar charts or dot plots.
A value of p& 0.05 was considered statistically significant. The exact p value
is given for each experiment.
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and six figures and can be found with this article online at https://doi.org/10.
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